<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04503447</url>
  </required_header>
  <id_info>
    <org_study_id>SARSCOV2SEROPREVALENCEITMSTAFF</org_study_id>
    <nct_id>NCT04503447</nct_id>
  </id_info>
  <brief_title>COVID-19 Seroprevalence Study in ITM Staff</brief_title>
  <acronym>CovAb</acronym>
  <official_title>Severe Acute Respiratory Syndrome Coronavirus (CoV) 2 (SARS-CoV-2) Seroprevalence Study in Institute of Tropical Medicine (ITM) Staff</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Tropical Medicine, Belgium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Belgium, the corona virus disease 2019 (COVID-19) epidemic is in the growing phase of its
      second wave.

      The Belgian crisis cell is balancing between allowing the economy to recover and minimize the
      disease spread. To decide which containment measures should be maintained, reinstalled or
      suspended, information on what proportion of people has been infected and on possible risk
      factors for virus transmission can be helpful.

      This study will be conducted on staff members of the ITM. All staff members will be invited
      to participate. Participants will be asked to have a blood sample drawn for detections of
      antibodies against SARS-CoV-2 (using one of these two commercial assays: Anti-SARS-CoV-2
      ELISA (EUROIMMUN) or WANTAI SARS-CoV-2 Ab ELISA (WANTAI SARS-CoV-2 Diagnostics)) and to
      complete a questionnaire about their exposure, both within and outside the ITM, to the
      SARS-CoV-2, and about their health and symptoms. The primary objective is to estimate the
      occurrence rate of anti-SARS-CoV-2 antibodies or seroprevalence in ITM staff. Secondary
      objective is to estimate the SARS-CoV-2 seroprevalence in ITM staff member groups, stratified
      by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to
      COVID-19 patients/samples, comorbidities, adherence to containment measures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is observational and will be conducted on ITM staff members. All members will be
      invited to participate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 seroprevalence ITM staff</measure>
    <time_frame>Sample is drawn once, at recruitment + 7 days maximum</time_frame>
    <description>The proportion of participating ITM staff members with detectable SARS-CoV-2 antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 seroprevalence in ITM staff, stratified by variables</measure>
    <time_frame>Questionnaire is completed once, at recruitment</time_frame>
    <description>SARS-CoV-2 seroprevalence in ITM staff members stratified by variables obtained through the questionnaire, such as age, gender, symptoms, exposure to COVID-19 patients/samples, comorbidities, adherence to containment measures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Risk or protective factors for SARS-CoV-2 seropositivity</measure>
    <time_frame>Questionnaire is completed once, at recruitment</time_frame>
    <description>To identify factors that are associated with an elevated or reduced risk of seropositivity in ITM staff and the Belgian working population in general.</description>
  </other_outcome>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Covid19</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Active ITM staff members
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be an active ITM staff member

          -  Be willing and able to complete the questionnaire

          -  Be willing and able to provide informed consent

        Exclusion Criteria:

          -  Doctor of Philosophy (PhD) students, Master students and interns of the ITM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marjan Van Esbroeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Tropical Medicine, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjan Van Esbroeck, MD</last_name>
    <phone>+32 3 247 64 44</phone>
    <email>mvesbroeck@itg.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Tropical Medicine</name>
      <address>
        <city>Antwerp</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Van Esbroeck, MD</last_name>
      <phone>+32 3 247 64 44</phone>
      <email>mvesbroeck@itg.be</email>
    </contact>
    <investigator>
      <last_name>Marjan Van Esbroeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Gils</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Laga</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikki Foqu√©</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bart Karl Jacobs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lut Lynen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2020</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>humans</keyword>
  <keyword>COVID-19</keyword>
  <keyword>pandemics</keyword>
  <keyword>SARS virus</keyword>
  <keyword>cross-sectional studies</keyword>
  <keyword>seroepidemiological studies</keyword>
  <keyword>Belgium</keyword>
  <keyword>risk factors</keyword>
  <keyword>seroprevalence</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study population being only ITM staff members, individual participant data (IPD) cannot be shared due to privacy reasons</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

